ANDA 71249, held by Quad Pharms. Cytarabine.
As of Nov 16, 2026, ANDA 71249 (Cytarabine), held by Quad Pharms, was not approved, with 0 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Cytarabine500MG/VIAL ยท injectable; injection | Cytarabine | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters